Abstract Neuroinflammation contributes to the pathophysiology of diverse diseases including stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, and multiple sclerosis, resulting in neurodegeneration and loss of neurological function. The response of the microvascular endothelium often contributes to neuroinflammation. One such response is the upregulation of endothelial adhesion molecules which facilitate neutrophil adhesion to the endothelium and their migration from blood to tissue. Neuregulin-1 (NRG1) is an endogenous growth factor which has been reported to have anti-inflammatory effects in experimental stroke models. We hypothesized that NRG1 would decrease the endothelial response to inflammation and result in a decrease in neutrophil adhesion to endothelial cells. We tested this hypothesis in an in vitro model of cytokine-induced endothelial injury, in which human brain microvascular endothelial cells (BMECs) were treated with IL-1β, along with co-incubation with vehicle or NRG1-β. Outcome measures included protein levels of endothelial ICAM-1, VCAM-1, and E-selectin, as well as the number of neutrophils that adhere to the endothelial monolayer. Our data show that NRG1-β decreased the levels of VCAM-1, E-selectin, and neutrophil adhesion to brain microvascular endothelial cells activated by IL1-β. These findings open new possibilities for investigating NRG1 in neuroprotective strategies in brain injury.
Abbreviations

ICAM-1 Intercellular cell adhesion molecule IL-1β
Interleukin-1 beta NRG1-β Neuregulin 1-beta VCAM-1 Vascular cell adhesion molecule-1 or vascular cell adhesion protein-1
Background
Neuroinflammation, the nonspecific immune reaction in the CNS that is characterized by increased microglia activation, presence of pro-and anti-inflammatory cytokines, blood brain barrier (BBB) permeability, and leukocyte invasion, is a key element of many different pathologies. It contributes to the pathophysiology of diverse diseases such as stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, and multiple sclerosis, and it is widely known to amplify the damage of the primary injury, resulting in neurodegeneration and loss of neurological function [1] . Release of both pro-and anti-inflammatory cytokines is a hallmark of the neuroinflammatory cascade, and the expression of these cytokines is strongly upregulated in the acute phase after many forms of brain injury [2, 3] . IL-1β is one of the major cytokines produced in the brain after injury, and IL-1β levels are directly correlated with the severity of inflammation [4] [5] [6] [7] . The microvascular endothelium contributes to the process of neuroinflammation through its response to the inciting damage and to circulating cytokines [8] . One such endothelial response is the upregulation of a class of proteins known as adhesion molecules, which can facilitate the adhesion of leukocytes to the endothelium and their migration from the blood to the tissue [8] . Beneficial effects of leukocyte recruitment include the ability of neutrophils to combat infections, while detrimental effects include the tissue destruction caused by the release of the contents of the neutrophil granules [9] . In many pathological conditions, an excessive inflammatory response to CNS pathologies contributes to secondary brain injury. A means of modulating this inflammatory response may therefore be of therapeutic value.
In this study, we determined the effect of NRG1-β on neutrophil adhesion to the endothelium. Using an in vitro model of cytokine-induced endothelial injury by incubation of human brain microvascular endothelial cells (BMECs) with IL-1β, we evaluated NRG1-β effect on endothelial levels of VCAM-1, ICAM-1, and E-selectin. Additionally, we assessed the effect of NRG1-β on the extent of neutrophil adhesion to BMECs which have been treated with IL-1β.
Materials and Methods
Animals
Mouse peritoneal neutrophils were obtained from adult CD1 female mice (2-5 months of age; Charles River Laboratories). The mice were housed for 12-h day/night cycles in a pathogen-free facility at Massachusetts General Hospital Institutional Animal Care in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals. Food and water were given ad libitum. All experiments followed the policies and guidelines of the Massachusetts General Hospital Institutional Animal Care and Use Committee.
Human brain microvascular endothelial cells (BMECs) (Cell systems, Kirkland, WA), passages 5 to 12, were grown in EBM-2 basal medium supplemented with Endothelial Cell Growth Medium-2 (Lonza, Walkersville, MD) unless otherwise specified. When 80-90 % confluent, cells were exposed to 50 ng/ml of IL-1β (Sigma, St. Louis, MO); along with different concentrations of NRG1-β (R&D, Minneapolis, MN) or vehicle. The NRG1-β used in all experiments consisted of the active domain of the NRG1-β isoform. The duration of incubation with vehicle or IL-1β was specified for each experiment. Experiments were performed in triplicate wells.
Neutrophil Adhesion Assay
The assay was performed three times with each condition tested in triplicate wells.
Preparation of Endothelial Cells A sterile 24-well plate was coated with 3 % collagen for 2 h and washed once with phosphate buffer solution. BMECs were seeded at a density of 1×10 5 /well. When >90 % confluent, these cells were treated for 6 h with vehicle (PBS) or IL-1β (doses as specified) +/− NRG1-β (doses as specified).
Neutrophil Activation and Retrieval CD1 mice (age range 2-5 months) were anesthetized and given an intraperitoneal (IP) injection of 2 mL of thioglycolate media (Sigma, St. Louis, MO) using a 27G needle. Eighteen to 24 h later, the mice were sacrificed, and an IP injection of 8 mL of RPMI 1640+1 % penicillin-streptomycin (Invitrogen, Grand Island, NY) was injected then collected with a 16G needle to retrieve the activated neutrophils.
Neutrophil Labeling and Collection MitroTracker Red CMXRos (Invitrogen Life Technologies) (1 mM) was added to the neutrophil collection at a 1:1000 dilution and incubated for 1 h in the cell incubator at 37°C, during which time neutrophils remain floating in the media and macrophages adhere to the bottom of the dish. The media containing the floating neutrophils was collected, and cells pelleted by centrifugation at 1,000-1,500 rpm for 5 min. Care was taken not to disrupt the surface of the dish in order to exclude the adherent macrophages. The pellet containing neutrophils was resuspended in EBM-2 cell medium.
Neutrophil Adhesion to Endothelial Cells CSC cells were treated for 6 h with PBS or IL-1β +/− NRG1-β as described above, after which 25,000 neutrophils (MitoTracker-labeled) were seeded onto the endothelial monolayer and incubated for 90 min at 37°C. Media was then removed, and each well was washed with phosphate buffer solution to remove nonadherent neutrophils. The cells were fixed with 4 % paraformaldehyde (PFA) for 20 min and examined by fluorescent microscopy.
Imaging and Quantification Three images (at ×200 magnification) were taken at random locations from each well. The number of neutrophils labeled with the fluorescent MitoTracker signal (which binds mitochondria in leukocytes but does not label red blood cells which lack mitochondria) was counted in each field. Only MitoTracker-labeled cells with a corresponding DAPI nuclear signal were counted. For visualization of cell morphology, an aliquot of the neutrophil suspension was concentrated by cytospin, Wright-Giemsa stained, and visualized at ×1000 magnification with light microscopy.
Western Blot Analysis
Cells were lysed with lysis buffer (Cell Signaling Technology, Beverly, MA, USA), and protein concentration was determined by Bradford assay (Bio-Rad, Hercules, CA, USA). Protein lysates (20 μg per lane) were separated in precast 4-12 % Tris-glycine SDS-polyacrylamide gels (Invitrogen, Grand Island, NY), and proteins were transferred to PVDF membranes (Invitrogen, Grand Island, NY). After blocking with 5 % nonfat milk, PVDF membranes were incubated overnight at 4°C with the following primary antibodies: rabbit anti-E-selectin (1:1000 dilution; Santa Cruz, Dallas, TX), rabbit anti-VCAM-1 (1:1000 dilution; Santa Cruz, Dallas, TX), mouse anti-ICAM-1 (1:1000 dilution; Santa Cruz, Dallas, TX). After washing, the membrane was incubated with peroxidase-conjugated secondary antibody at room temperature for 1 h. Antigen-antibody complexes were visualized with the ECL chemiluminescence system (Amersham, Piscataway, NJ) and exposed to a Kodak X-OMAT film (Kodak, Rochester, NY, USA). The relative densities of bands were analyzed with NIH Image J.
Assessment of Cytotoxicity
IL-1β -induced cytotoxicity was quantified by a standard measurement of lactate dehydrogenase (LDH) release with the use of the LDH assay kit (Boehringer-Mannheim, Ingelheim am Rhein). Percent cytotoxicity was calculated by comparing LDH released into the media to the total LDH content in viable cells and media. In addition, cytotoxicity was also quantified by measurement of the reduction of 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide (MTT) to produce a dark blue formazan product. This assay assesses the integrity of mitochondrial function. MTT was added to each culture well at indicated time points after hemoglobin exposure at a final concentration of 0.5 % MTT solution (wt/vol). After 3 h (h) at 37°C, the media was removed and cells were dissolved in dimethyl sulfoxide. The formation of formazan was measured by reading absorbance at a wavelength of 570 nm with a reference setting of 630 nm on a microplate reader (model FL600, Bio-Tek Instruments, Winooski, VT). Both LDH and MTT reduction assays were used to ensure that similar data were obtained after druginduced cytotoxicity.
Statistical Analysis
Statistical analysis was performed by mixed model regression followed by Tukey HSD for multiple comparisons for evaluation of protein levels, and by ANOVA followed by Tukey HSD for evaluation of neutrophil number. Statistical significance was set at p<0.05. Quantitative data for experiments were expressed as mean±standard deviation (SD).
Results
NRG1-β Ameliorates the IL-1β-Induced Increase in Endothelial VCAM-1 and E-Selectin
Prior to investigating the effect of IL-1β on endothelial expression of adhesion molecules and on neutrophil expression, we demonstrated that IL-1β did not cause endothelial cell death in this model of cytokine-induced endothelial inflammation (Fig. 1a) . Additionally, pilot experiments were performed to determine the dose-dependent effects of IL-1β on adhesion protein levels and on neutrophil adhesion. Based on these pilot data, an IL-1β dose of 50 ng/ml and an incubation time of 6 h were used for the experiments on adhesion molecule levels.
IL-1β challenge resulted in an increase in VCAM-1, ICAM-1, and E-selectin. VCAM-1 protein level in IL-1β-treated cells was 5 (5.1 +/− 1.0, p <0.05) times that of untreated controls. Addition of 100 ng/ml (12.5 nM) NRG1-β did not lead to a statistically significant difference from IL-1β-treated cells. Addition of a higher dose (300 ng/ml or 37.5 nM) of NRG1-β resulted in a decrease in VCAM-1 to 3.5 (3.5 +/− 1.2) times that of IL-1β-treated cells in the absence of NRG1-β, a statistically significant reduction of 32 % (p<0.05), (Fig. 2a) . Based on this result, a NRG1-β dose of 300 ng/ml (37.5 nM) was used in subsequent experiments for evaluating the NRG1 effect on IL-1β induced increases in ICAM-1 and E-selectin protein levels. The protein level of ICAM-1 in IL-1β-treated cells was five (4.9 +/− 1.5, p<0.05) times that of untreated controls. In the presence of NRG1, ICAM-1 protein level was 4.2× that of IL-1β-treated cells, which did not represent a statistically significant difference (Fig. 2b) . The protein level of E-selectin in IL-1β-treated cells was 3.3 (3.3 +/− 0.6; p<0.05) times that of untreated controls. Fig. 1 Incubation of BMEC with IL-1β does not result in an increase in cell death or a decrease in metabolic activity. After incubation with IL-1β (100 ng/ml) for 18 h in the presence of vehicle or NRG1-β (100 ng/ml or 300 ng/ml), changes in metabolic activity and cell death of BMECs were evaluated by LDH (right axis) or MTT assay (left axis). For MTT results, the data is represented as the percent of metabolic activity compared to the vehicle-treated control (shown as the mean+SEM). For LDH, the results are expressed as the value of % LDH release for each condition (shown as the mean+SEM). n=3
Addition of NRG1-β resulted in a decrease in E-selectin levels to 2.4 (2.4 +/− 0.8) times that of IL-1β-treated cells, a statistically significant decrease of 27 % (p<0.05) (Fig. 2c) .
NRG1-β Reduces the IL-1β-Induced Increase in Neutrophil Adhesion in Human Brain Endothelial Cells
We further explored whether the effect of NRG1-β on endothelial adhesion molecules extended to a change in the level of neutrophil adhesion. In a neutrophil adhesion assay, activated mouse peritoneal neutrophils were used. Light microscopy of Wright-Giemsa stained cells in the suspension revealed that >90 % of the leukocytes had morphology consistent with neutrophils (Fig. 3a, d ). Variable numbers of erythrocytes were present in different preparations, depending on the amount of capillary blood entrained into the fluid collected during the neutrophil retrieval process. However, erythrocytes do not contain mitochondria and hence do not incorporate the fluorescent MitoTracker signal, while the labeled neutrophils appear brightly fluorescent (Fig. 3b, c) . DAPI staining showed that the MitoTracker labeling corresponded to cells rather than to nonspecific debris.
Within the pilot series of experiments to determine the appropriate IL-1β dosage for the neutrophil adhesion assay, IL-1β doses of 10, 50, and 100 ng/ml were tested. There was a dose-dependent increase in the number of adherent neutrophils, and addition of NRG1-β reduced neutrophil adhesion at each IL-1β concentration (Fig. 4a-g and h) . Because this was a pilot series, three separate experiments were not performed at all doses; however, the consistency of NRG-1β effect across the different IL1-β concentrations supports the hypothesis that NRG1 has an effect on neutrophil adhesion.
In the neutrophil adhesion assay using an IL-1β dose of 50 ng/ml, an average of 14 (14 +/− 6.5) adherent neutrophils were seen per field of BMECs treated with vehicle (PBS). In IL-1β-treated endothelial cells, the number of adherent neutrophils increased to 35 (35+/− 12.9) per high-powered field, a 2.5-fold increase (p<0.05) over baseline. In endothelial cells that were treated with IL-1β and100 ng/ml (12.5 nM) NRG1-β, the number of adherent neutrophils decreased to 14 (14.6 +/− 4.7), a significant decrease back to baseline levels (p<0.05). In endothelial cells treated with IL-1β and 300 ng/ml (37.5 nM) NRG1-β, the number of adherent neutrophils was 9.9 (9.9 +/− 4.0), again a significant decrease from that in cells treated with IL-1β without NRG1-β (p<0.05), (Fig. 5) .
Discussion
Our previous data show that NRG1-β prevents endothelial hyper-permeability during IL-1β induced injury, and Fig. 2 NRG1-β decreases IL-1β induced increases in protein levels of endothelial intercellular adhesion molecules. BMECs were treated with IL-1β (50 ng/ml) and co-incubated addition vehicle (PBS) or NRG1-β (12.5 nM and/or 37.5 nM). Western blots of cell lysates were analyzed for protein levels of adhesion molecules. n=3. a 6 h incubation with IL-1β resulted in an increase in a 5-fold (5.1 +/− 1.0, p<0.05) increase in VCAM-1. Co-incubation with 100 ng/ml (12.5 nM) NRG1-β did not result in a statistically significant difference from IL-1β-treated cells; however, addition of 300 ng/ml (37.5 nM) NRG1-β resulted in a decrease in VCAM-1 levels to 3.5 (3.5 +/− 1.2) times that of IL-1β-treated cells that were co-incubated with vehicle, which is a statistically significant reduction of 32 % (p<0.05).n=3. b 6 h incubation with IL-1β resulted in a 5-fold (4.9 +/− 1.5, p<0.05) increase in endothelial ICAM-1 levels compared to vehicle-treated controls. BMECs that were co-incubated with NRG1 (300 ng/ml or 37.5 nM) had ICAM-1 protein levels which were 4.2×that of IL-1β-treated cells, which does not represent a statistically significant difference. c 6 h incubation with IL-1β resulted in an increase in endothelial E-selectin expression, averaging 3.3-fold (3.3 +/− 0.6; p<0.05) increase compared to baseline (*p<0.01). Co-incubation with 300 ng/ml (37.5 nM) NRG1-β resulted in a decrease in E-selectin levels to 2.4 (2.4 +/− 0.8) times that of IL-1β-treated cells that were coincubated with vehicle, a statistically significant decrease of 27 % (p<0.05) (Fig. 2c) . n=3 ameliorates acute increases in BBB permeability following brain trauma [10] . Here we show that NRG1-β reduces the IL-1β induced increase in protein levels of VCAM-1 and Eselectin, and in neutrophil adhesion to endothelial cells.
IL-1β is upregulated rapidly in the brain after diverse forms of brain injury, especially in the hippocampus and cortical areas. After subarachnoid hemorrhage and severe head trauma in humans, IL-1β levels peak on day 2 at 26.9±4.5 pg/ml, followed by a gradual decline [11] . Analysis of IL-1β levels from brain microdialysates from TBI patients yielded a mean IL-1β concentration of 10.4 +/− 14.7 pg/mL [12] . The IL-1β dose used in our study is of a higher level than that reported from these clinical series; however, it is consistent with the range of concentrations used in other in vitro experiments that study the interaction of endothelial cells with IL-1β. It is possible that when a single type of cell is being studied in in vitro experiments without the normal components of the neurovascular unit, synergistic cellular interactions that amplify cellular responses do not occur, and therefore a higher concentration of IL-1β is required to obtain a clear signal above background. In a study investigating the effect of IL-1β on endothelial permeability, the half-maximal effective concentration of IL-1β used to induce endothelial permeability during a 6-h incubation was 53 ng/ml. [13] . In studies involving the IL-1β effect on endothelial activation and expression of adhesion molecules, IL-1β doses used ranged from pg/ml [14] to ng/ml [15] . In our dose-finding experiment, activating endothelial cells with IL-1β doses of 10 ng/ml, 50 ng/ml, and 100 ng/ml resulted in a dosedependent increase in neutrophil adhesion. In order to obtain a reasonable signal to background ratio, an IL -1β dose of 50 ng/ml was used.
Neuregulin1-β (NRG1-β) is an endogenous growth factor which plays multiple functions in the embryonic and postnatal central nervous system [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . NRG1/erbB signaling is known to be involved in many functions in neurons and glia [17, 18, 26] , and its involvement in the peripheral microvascular endothelium has been increasingly clarified [27] [28] [29] . It was recently demonstrated that NRG1/erbB signaling is active in microvascular endothelial cells of the brain [30] and that NRG1-β decreases pathological increases in endothelial permeability induced by IL-1β [10] . Our current data show that NRG1-β decreases the expression of VCAM-1 and E-selectin in BMECs that have been activated by IL-1β, and modulates the IL-1β induced increase in neutrophil adhesion to endothelial cells.
These findings are consistent with previous reports of the anti-inflammatory actions of NRG1. In in vitro studies, the NRG1 isoform GGF2 was reported to reduce free radical release from activated microglial cells [31] . A separate group also found that NRG-1 induces a decrease in the proinflammatory cytokines TNF-α and IL-6 in microglial cells challenged with lipopolysaccharide [32] . In animal studies, reduced levels of type III NRG1 transcripts were observed in immunodeficient mice [33] , and NRG1 was found to attenuate inflammatory responses induced by ischemic stroke [34] . Findings from human studies yielded consistent data in this regard. Studies using cell lines from patients with Fig. 3 Representative images of neutrophils and endothelial cells in the neutrophil adhesion assay. a Cytopsin of mouse peritoneal neutrophils, Wright-Giemsa stained, photographed at ×400. b High magnification view of neutrophils with fluorescent MitoTracker signal, photographed at ×400. c Neutrophils and endothelial cells in neutrophil adhesion assay, photographed at ×200. d Mouse peritoneal neutrophils, WrightGiemsa stained, photographed at ×1000 Fig. 4 IL-1β dose-finding pilot experiment for neutrophil adhesion assay. At 10 ng/ml (n= 2), IL-1β increased the neutrophil adhesion 1.8-fold that of the baseline level; at 50 ng/ml (n=3): 2.5-fold; at 100 ng/ml (n=1): 4-fold. Co-incubation of NRG1-β (300 ng/ml or 37.5 nM) reduced neutrophil adhesion at each dose of IL-1β. a-g Representative images of the neutrophil adhesion assay with the conditions listed. h Graphical representation of the results of the dose-finding pilot experiment schizophrenia and from controls suggest that NRG1-α affects the migration of immune cells [35] . In another human study, a mutation in the transmembrane domain of the NRG-1 protein was linked to dysregulation of the immune system resulting in an increase of pro-inflammatory cytokines IL-6, TNF-α, and IL-1β as well as a reduced expression of the antiinflammatory cytokine IL-4 [36] . On the other hand, NRG1 actions may differ depending on the cell type and context. There have been reports that NRG1/erbB signaling may increase inflammation in some conditions -for instance, NRG1/erbB signaling has been reported to promote microglial proliferation and chemotaxis in an animal model of peripheral nerve injury [37] . In patients with acute lung injury, elevated bronchial levels of NRG1 was reported to be associated with level of inflammation, although it is not clear whether there is a causal relationship [38] .
Our current in vitro model is consistent with NRG1 effects in the setting of acute inflammation. It is important to keep in mind that neuroinflammation has both deleterious and protective properties in the different phases after injury. In the acute phase, inflammation may exacerbate tissue damage; while in the recovery phase inflammation may promote endogenous repair [39] . However, prolonged inflammation may outweigh endogenous regenerative reactions [40, 41] . Given these considerations, further translational studies will be needed to determine the optimal time for exogenous administration of NRG1 as its anti-inflammatory activity effects during the acute phase may impact on the balance between beneficial and deleterious effects of the inflammatory response in the acute and recovery phase.
Although this study focuses on the effect of NRG1 on the expression of endothelial adhesion molecules and the subsequent adhesion of neutrophils, one might speculate on possible NRG1 effects on other physiological processes associated with these adhesion molecules. A relevant example is that of the migration of bone marrow derived endothelial progenitor cells (EPC) to the site of brain injury, since adhesion molecules such as VCAM-1 are involved in this process [42] . The question may arise as to whether the modification of adhesion molecule expression by NRG1 could render the environment less conducive to EPC migration towards damaged tissue. Although NRG1's effect on EPC migration towards a site of CNS injury has not been studied, there is evidence that NRG1 is involved in EPC function. Transcripts of NRG1 receptors erbB2 and erbB3 have been found in EPCs isolated from rat bone marrow, human whole blood, and an embryonic EPC (eEPCs) cell line [43] , and NRG1 has been reported to affect survival of eEPCs by inhibiting serum deprivation-induced apoptosis [43] . These findings suggest that NRG1 signaling has the potential to support EPC function during the recovery phase of injury, although it is not known whether this benefit is mediated through an effect on EPC survival, migration, or other angiogenic processes. Separate from its potential interactions with EPC migration, NRG1 effect on blood flow recovery in a rodent model of limb ischemic injury suggests that it has favorable actions on the vasculature after ischemia. In this model, deletion of endothelial NRG decreased blood flow recovery and arteriogenesis, while administration of exogenous NRG1-β enhanced blood flow recovery [44] .
There are limitations to our study. Our in vitro experiments, which utilize a cell line, do not capture the complex events that occur in vivo during an inflammatory process. Interactions with other cellular elements, such as macrophages, lymphocytes, and platelets are not included, or with proteins in the serum. We have focused on one time point (6 h) in the IL-1β interaction with BMECs and one time point (90 min) in the process of neutrophil/endothelial adhesion, when both of these events likely involve many dynamic changes. The study of a single cell type does not re-capitulate the complex interactions within the neurovascular unit. The use of one dose of IL-1β used (50 ng/ml) does not accurately capture the different types of inflammatory microenvironments in the setting of various CNS pathologies.
Conclusion
Neuroinflammation can lead to many immediate and longterm harmful sequelae. Neutrophil migration into the tissue is a central event in neuroinflammation. Our data suggest that NRG1-β reduces cytokine-induced neutrophil adhesion, one In PBS-treated BMECs, an average of 14 (14 +/− 6.5) neutrophils were adherent to the endothelial monolayer in each field. In IL-1β-treated endothelial cells, the number of adherent neutrophils increased to 35 (35 +/− 12.9), a 2.5 fold increase (p<0.05). In BMECs treated with IL-1β and co-incubated with NRG1-β (100 ng/ml or 12.5 nM) NRG1-β, the number of adherent neutrophils decreased to the baseline level of 14 (14.6 +/− 4.7; p<0.05compared to BMECs treated with IL-1β and co-incubated with PBS). In endothelial cells treated with IL-1β and 300 ng/ml (37.5 nM) NRG1-β, the number of adherent neutrophils was 9.9 (9.9 +/− 4.0), again a significant decrease from that in cells treated with IL-1β without NRG1-β (p<0.05) of the initial steps in the process of neutrophil recruitment and migration. These findings may open new possibilities for investigating NRG1's potential in neuroprotection in inflammatory conditions in the CNS.
